News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News Immunocore hires Lilly's Hotchkiss as chief commercial offic... UK biotech leading in the nascent field of TCR immunotherapy has appointed Andrew Hotchkiss as its new Chief Commercial Officer.
News Opdivo and Tafinlar+Mekinst hailed in earlier melanoma treat... Two new regimens look set to transform treatment to delay melanoma returning in patients after surgery.
News NICE recommends Amgen’s melanoma treatment after price cut Drug only approved when systemic immunotherapies are not suitable
News Imbruvica, Opdivo and Praluent gain approvals for Scotland’s... Sanofi steals a march on rivals Amgen
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.